213 related articles for article (PubMed ID: 8150554)
1. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.
Collinson AR; Lambert JM; Liu Y; O'Dea C; Shah SA; Rasmussen RA; Goldmacher VS
Int J Immunopharmacol; 1994 Jan; 16(1):37-49. PubMed ID: 8150554
[TBL] [Abstract][Full Text] [Related]
2. Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.
Rasmussen RA; Counts SL; Lambert JM; Collinson AR
Cancer Immunol Immunother; 1992; 35(5):355-63. PubMed ID: 1394340
[TBL] [Abstract][Full Text] [Related]
3. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
Goldmacher VS; Bourret LA; Levine BA; Rasmussen RA; Pourshadi M; Lambert JM; Anderson KC
Blood; 1994 Nov; 84(9):3017-25. PubMed ID: 7524764
[TBL] [Abstract][Full Text] [Related]
5. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
Grossbard ML; Lambert JM; Goldmacher VS; Blättler WA; Nadler LM
Cancer Res; 1992 Aug; 52(15):4200-7. PubMed ID: 1379121
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.
Shah SA; Lambert JM; Goldmacher VS; Esber HJ; Levin JL; Chungi V; Zutshi A; Braman GM; Ariniello PD; Taylor JA
Int J Immunopharmacol; 1993 Aug; 15(6):723-36. PubMed ID: 7691767
[TBL] [Abstract][Full Text] [Related]
7. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
8. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
9. [Preparation and study of cytotoxic properties of the immunotoxin anti-CD7/A-chain of ricin].
Tonevitskiĭ AG; Ershova GV; Agapov II; Toptygin AIu; Korotkova OV; Shereshkov SN; Kadagidze ZG; Baryshnikov AIu
Dokl Akad Nauk SSSR; 1991; 317(3):749-53. PubMed ID: 1720085
[No Abstract] [Full Text] [Related]
10. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
Grossbard ML; Freedman AS; Ritz J; Coral F; Goldmacher VS; Eliseo L; Spector N; Dear K; Lambert JM; Blättler WA
Blood; 1992 Feb; 79(3):576-85. PubMed ID: 1370636
[TBL] [Abstract][Full Text] [Related]
11. Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26.
Duke-Cohan JS; Morimoto C; Schlossman SF
Blood; 1993 Oct; 82(7):2224-34. PubMed ID: 8104537
[TBL] [Abstract][Full Text] [Related]
12. Selective killing of tumor cells in vitro by an immunotoxin composed of ricin and monoclonal antibody against Ia antigen.
Wu M; Tang SL; Zang RJ; Yu H
Int J Immunopharmacol; 1990; 12(2):235-9. PubMed ID: 2329015
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
Fishwild DM; Aberle S; Bernhard SL; Kung AH
Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
[TBL] [Abstract][Full Text] [Related]
14. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA
Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599
[TBL] [Abstract][Full Text] [Related]
15. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
16. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
[TBL] [Abstract][Full Text] [Related]
17. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
[TBL] [Abstract][Full Text] [Related]
18. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer.
Epstein C; Lynch T; Shefner J; Wen P; Maxted D; Braman V; Ariniello P; Coral F; Ritz J
Int J Cancer Suppl; 1994; 8():57-9. PubMed ID: 7515030
[TBL] [Abstract][Full Text] [Related]
19. Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.
Chiron M; Jaffrezou JP; Carayon P; Bordier C; Roubinet F; Xavier C; Brandely M; Laurent G
Clin Exp Immunol; 1990 Nov; 82(2):214-20. PubMed ID: 2122930
[TBL] [Abstract][Full Text] [Related]
20. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
